Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Neven

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Breast Cancer Research and Treatment|August 10, 2007
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancerP Neven, B Van Calster, I Van den Bempt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 1, 2017
Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitorsT van Cann, T Loyson, A Verbiest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialK L Jhaveri, P Neven, M L Casalnuovo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2022
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancerK Van Baelen, T Geukens, M Maetens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancerK Van Baelen, E Sawyer, J Van Cauwenberge, et al.
Clinical Pharmacology and Therapeutics|September 25, 2013
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsM A Province, M P Goetz, H Brauch, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Breast Cancer Research and Treatment|August 10, 2007
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancerP Neven, B Van Calster, I Van den Bempt, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 1, 2017
Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitorsT van Cann, T Loyson, A Verbiest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialK L Jhaveri, P Neven, M L Casalnuovo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2022
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancerK Van Baelen, T Geukens, M Maetens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancerK Van Baelen, E Sawyer, J Van Cauwenberge, et al.
Clinical Pharmacology and Therapeutics|September 25, 2013
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsM A Province, M P Goetz, H Brauch, et al.
Pageof 14